Renal safety of a tenofovir-containing first line regimen: Experience from an antiretroviral cohort in rural lesotho

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Bygrave, Helen ^a   Kranzer, Katharina ^b   Hilderbrand, Katherine ^a,c   Jouquet, Guillaume ^a   Goemaere, Eric ^a   Vlahakis, Nathalie ^a   Triviño, Laura ^a   Makakole, Lipontso ^d   Ford, Nathan ^a,c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Scott Hospital   (Lesotho)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; TENOFOVIR; ZIDOVUDINE; ADENINE; ANTIRETROVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; LESOTHO; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; RARE DISEASE; RISK FACTOR; RURAL AREA; TREATMENT DURATION; ALGORITHM; COHORT ANALYSIS; DRUG EFFECT; FOLLOW UP; HEALTH CARE QUALITY; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; RURAL POPULATION;

ADENINE; ADULT; ALGORITHMS; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LESOTHO; MALE; PHOSPHONIC ACIDS; PROGRAM EVALUATION; RISK FACTORS; RURAL POPULATION;

EID: 79952297768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017609     Document Type: Article

References (19)

1. Anon, (2009) Rapid Advice; Antiretroviral Therapy for HIV infection in adults and adolescents. Geneva World Health Organization.
2. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201.
3. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine 354: 251-60.
4. Pozniak A, (2008) Tenofovir: what have over 1 million years of patient experience taught us? International Journal of Clinical Practice 62: 1285-93.
5. Grim SA, Romanelli F, (2003) Tenofovir disoproxil fumarate The Annals of pharmacotherapy. Annals of Pharmacotherapy 37: 849-59.
6. Anon, (2010) Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva World Health Organization.
7. Anon, (2010) Clinical guidelines for the management of HIV and AIDS in Adults and Adolescents. Pretoria National Department of Health South.
8. Cohen R, Lynch S, Bygrave H, Eggers E, Vlahakis N, et al. (2009) Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. Journal of the International AIDS Society, 2009 12: 23.
9. Schopper D, Upshur R, Matthys F, Singh JA, Bandewar SS, et al. (2009) Research ethics review in humanitarian contexts: the experience of the independent ethics review board of Médecins Sans Frontières. PLoS Med 6: 7.
10. Mulenga L, Kruse G, Lakhi S, Cantrell R, Reid S, (2008) Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 22: 1821-1827.
11. Franey C, Knott D, Barnighausen T, Dedicoat M, Cooke GS, (2009) Renal impairment in a rural African antiretroviral programme. BMC Infectious Diseases 9: 143.
12. Struik G, den Exter R, Munthali A, (2010) The Prevalence of Renal Impairment among WHO stage 1 and 2, HIV positive, ANti Retroviral naive, patients in Blantyre, Malawi. XVIII Conference of the International AIDS Society conference Vienna.
13. Keiser O, Anastos K, Schechter M, Balestre E, et al. ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA) (2008) Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 13: 870-9.
14. Cooper R, Wiebe N, Smith N, Keiser P, Naicker S, (2010) Systematic Review and Meta Analysis: Renal Safety of Tenfovir Disoproxil Fumarate in HIV- Infected Patients. Clinical Infectious Diseases 51: 496-505.
15. Chi B, Mwango A, Gignti M, Mulenga L, Tambatamba-Chapula B, (2010) Early Clinical and Programmatic Outcomes with Tenofovir-Based Antiretroviral Therapy in Zambia. J Acquir Immune Defic Syndr 54: 63-70.
16. Reid A, Stohr W, Walker S, Hakim J, Ssali F, et al. on behalf of the DART trial (2005) Glomerular dysfunction and associated risk factors following initiation of ART in adults with HIV infection in Africa. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Capetown. Abstract ThAB0105.
17. Vrouenraets S, Garcia E, Wit F, Brinkman M, Hoek C, (2008) A comparison between different GFR estimations and (125) Iothalamate, the gold standard for GFR measurements in HIV infected patients on HAART. 15th Conference on Retroviruses and Opportunistic Infections: Boston. Abstract 977b.
18. Barraclough K, Er L, Ng F, Harris M, Montaner J, et al. (2009) A comparison of the predictive performance of different methods of kidney function estimation in a well characterised HIV-infected population. Nephron Clin Pract 111: 39-48.
19. Verhave JC, Fesler P, Ribstein du Cailar G, Mimran A, (2005) Estimation of renal function in subjetcs with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 46: 233-241.